Latest Infliximab Stories
As guidelines recommend, doctors appear to be stopping anti-TNF medications before surgery, but may be doing so far sooner than is necessary.
According to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago, people taking anti-tumor necrosis factor therapies to treat rheumatoid arthritis
Biological agents used to treat rheumatoid arthritis seem to be associated with an increased risk of skin cancer, indicates a systematic review of published research in the Annals of the Rheumatic Diseases.
HORSHAM, Pa., July 21, 2011 /PRNewswire/ -- Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S.
GREENWOOD VILLAGE, Colo., May 31, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE)("Ampio") announced today that it received ethics board approval for a Phase 1B clinical trial in Australia of its biologic anti-inflammatory agent, Ampion(TM).
LONDON, May 25, 2011 /PRNewswire/ -- Results from a Phase 2 multicenter, randomized, double-blind, proof-of-concept and dose-finding study showed that treatment with sirukumab (CNTO 136) improved signs and symptoms of rheumatoid arthritis (RA) in patients with active disease despite treatment with methotrexate (MTX).
SEOUL, Korea, May 25, 2011 /PRNewswire/ -- New findings presented from pooled analyses of the STELARAÂ® (ustekinumab) psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.